{"id":396854,"date":"2025-04-03T08:11:16","date_gmt":"2025-04-03T06:11:16","guid":{"rendered":"https:\/\/medizinonline.com\/durvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc\/"},"modified":"2025-04-03T08:15:54","modified_gmt":"2025-04-03T06:15:54","slug":"durvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/durvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc\/","title":{"rendered":"Durvalumab \u00e8 stato approvato come prima immunoterapia per i pazienti con LS-SCLC"},"content":{"rendered":"\n<p><strong>Durvalumab \u00e8 stato approvato come monoterapia in Svizzera per il trattamento di pazienti adulti con carcinoma polmonare a piccole cellule non resecabile (LS-SCLC, <em>carcinoma polmonare a piccole cellule in stadio limitato) <\/em>la cui malattia non \u00e8 progredita dopo la chemioradioterapia (CRT) a base di platino [1]. Offre una nuova opzione terapeutica che ha dimostrato di migliorare la sopravvivenza dei pazienti con questa forma aggressiva di cancro al polmone. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fdurvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Durvalumab \u00e8 stato approvato come monoterapia in Svizzera per il trattamento di pazienti adulti con carcinoma polmonare a piccole cellule non resecabile (LS-SCLC, carcinoma polmonare a piccole cellule in stadio&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fdurvalumab-e-stato-approvato-come-prima-immunoterapia-per-i-pazienti-con-ls-sclc%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":396857,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Carcinoma polmonare a piccole cellule","footnotes":""},"category":[11550,11537,11376,11468,11515],"tags":[11712,37858,23748,13611,81889,20514,23119],"powerkit_post_featured":[],"class_list":["post-396854","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-it","category-mercato-e-medicina","category-oncologia-it","category-pneumologia","category-studi","tag-cancro-al-polmone","tag-chemioterapia-it-2","tag-durvalumab-it","tag-immunoterapia","tag-lc-sclc-it","tag-sclc-it","tag-tumore-al-polmone-a-piccole-cellule","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-01 01:32:24","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":396848,"slug":"durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc","post_title":"Durvalumab aprovado como primeira imunoterapia para doentes com LS-SCLC","href":"https:\/\/medizinonline.com\/pt-pt\/durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc\/"},"es_ES":{"locale":"es_ES","id":396842,"slug":"durvalumab-aprobado-como-primera-inmunoterapia-para-pacientes-con-ls-sclc","post_title":"Durvalumab aprobado como primera inmunoterapia para pacientes con LS-SCLC","href":"https:\/\/medizinonline.com\/es\/durvalumab-aprobado-como-primera-inmunoterapia-para-pacientes-con-ls-sclc\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/396854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=396854"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/396854\/revisions"}],"predecessor-version":[{"id":398119,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/396854\/revisions\/398119"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/396857"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=396854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=396854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=396854"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=396854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}